Biomea Reports Phase 1 Weight-Loss Data For Oral GLP-1 Candidate BMF-650; Shares Fall

Biomea Fusion reported Phase 1 results for BMF-650, an investigational oral GLP-1 receptor agonist in development for obesity and metabolic disorders. The article excerpt provides no efficacy, safety, or other trial data, so the results’ implications cannot be assessed.